NeoGenomics, a clinical laboratory company based in Fort Myers, Florida, specializes in cancer genetics diagnostic testing and pharma services, employing 2,100 staff since its IPO in December 2012. Its services include clinical cancer testing and advanced diagnostics for healthcare providers and pharmaceutical companies.
NEO has been in the news recently: ConcertAI and NeoGenomics have introduced CTO-H, a software solution that utilizes a dataset of over 370,000 patients to improve research and clinical trials for hematological malignancies. Following this launch, shares of NeoGenomics Inc increased by 4.33% to $17.94, with analysts predicting a target price of $20.50, suggesting a possible 14.30% rise.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
